Tarsus Pharmaceuticals: Xdemvy Momentum Continues In Q3

Tarsus Pharmaceuticals, Inc. is upgraded to Strong Buy with a 12-month price target of $100/share, driven by Xdemvy's rapid commercialization. Xdemvy remains the only approved treatment for Demodex blepharitis, with accelerating sales growth and significant untapped patient population in the U.S. TARS is poised for further upside from global expansion, robust pipeline, and an earnings inflection expected in 2026 as revenue growth achieves profitability.

Seeking Alpha • Nov 20, 2025

Tarsus Pharmaceuticals, Inc. (TARS) Q3 2025 Earnings Call Transcript

Tarsus Pharmaceuticals, Inc. ( TARS ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants David Nakasone - Head of Investor Relations Bobak Azamian - Co-Founder, President, CEO & Chairman Aziz Mottiwala - Chief Commercial Officer Jeffrey S. Farrow - CFO & Chief Strategy Officer Seshadri Neervannan - Chief Operating Officer Conference Call Participants Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Eddie Hickman - Guggenheim Securities, LLC, Research Division Jason Gerberry - BofA Securities, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C.

Seeking Alpha • Nov 5, 2025

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

Delivered quarterly  XDEMVY ® net sales of approximately $119 million, up approximately 147% year-over-year

GlobeNewsWire • Nov 4, 2025

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Beats Revenue Estimates

Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.61 per share a year ago.

Zacks Investment Research • Nov 4, 2025

Tarsus to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

IRVINE, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 1:30 p.m. PT / 4:30 p.m. ET on Tuesday, November 4, 2025 to report its third quarter 2025 financial results and provide a corporate update.

GlobeNewsWire • Oct 28, 2025

Tarsus Pharmaceuticals (TARS) Moves 10.9% Higher: Will This Strength Last?

Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Oct 6, 2025

Tarsus Pharmaceuticals: Considering If The Big Marketing Push Will Pay Off

TARS has passed the milestone of $100M in sales per quarter with Xdemvy. TARS guides for softer Q3'25 growth due to seasonality, but expects direct-to-consumer campaigns and reimbursement to drive stronger growth in Q4'25 and beyond. TARS pipeline includes international Xdemvy launches and a new ocular rosacea trial, offering significant future revenue potential beyond current indications.

Seeking Alpha • Sep 26, 2025

Tarsus to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences:

GlobeNewsWire • Aug 27, 2025

3 Biotech Catalysts Present Major Opportunity

For biotech firms, a bit of positive news—a key result from clinical trials or new drug discovery, say—can be the difference between a major rally based on a path toward sustained profitability and a slump that can lead to the firm's eventual demise.

MarketBeat • Aug 25, 2025

Top 2 Health Care Stocks That May Fall Off A Cliff In August

As of Aug. 20, 2025, two stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Aug 20, 2025